TC Biopharm begins phase 2B study evaluating Omnimmune to treat acute myeloid leukemia

Nov. 22, 2022 8:57 AM ETTC Biopharm (Holdings) Plc (TCBP)By: Dania Nadeem, SA News Editor
  • TC Biopharm (NASDAQ:TCBP) is trading ~4% higher after it begun dosing first three patients in its Phase 2b trial of OmnImmune, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia.
  • The first 5 patients in the trial will be a "safety cohort", spaced

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.